

Yunki Y Yau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1836504/publications.pdf>

Version: 2024-02-01

16
papers

296
citations

1163117

8
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

560
citing authors

#	ARTICLE	IF	CITATIONS
1	Reflux scintigraphy in gastro-esophageal reflux disease: a comparison study with 24-hour pH-impedance monitoring. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-5.	1.5	1
2	Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 292-301.	3.7	39
3	Current Trends in IBD Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. <i>Inflammatory Bowel Diseases</i> , 2021, 27, S17-S24.	1.9	6
4	Spp24 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for "leaky-gut" in inflammatory bowel disease. <i>Scientific Reports</i> , 2020, 10, 12932.	3.3	13
5	Knowledge and Attitudes Towards Pregnancy in Females with Inflammatory Bowel Disease: An International, Multi-centre Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1248-1255.	1.3	27
6	Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission confounded by the gut microbiome?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1086-1087.	3.7	2
7	IDDF2019-ABS-0042...Prospective study of risk score strategies in the prediction of advanced colorectal neoplasia at colonoscopy. , 2019, , .		0
8	Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases. <i>Proteomes</i> , 2018, 6, 17.	3.5	77
9	Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 735-740.	1.6	10
10	Full-Spectrum Endoscopy Improves Surveillance for Dysplasia in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 1337-1344.e3.	1.3	30
11	Serological Epithelial Component Proteins Identify Intestinal Complications in Crohn's Disease. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1244-1257.	3.8	13
12	Proteomics in Inflammatory Bowel Disease: Approach Using Animal Models. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2266-2276.	2.3	6
13	Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 256-265.	3.8	30
14	Reverse-Polynomial Dilution Calibration Methodology Extends Lower Limit of Quantification and Reduces Relative Residual Error in Targeted Peptide Measurements in Blood Plasma. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 441-454.	3.8	3
15	Bimodal plasma metabolomics strategy identifies novel inflammatory metabolites in inflammatory bowel diseases. <i>Discovery Medicine</i> , 2014, 18, 113-24.	0.5	7
16	Proteomics and metabolomics in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1076-1086.	2.8	32